Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
ConditionCardiac Amyloidosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorUniversity Hospital, Essen
About this trial
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
Eligibility criteria
Qualifiers
Age > 40 years
proven Amyloidosis (ATTR or AL)
Women: negative pregnancy test less than weeks prior imaging.
Disqualifiers
Patients receiving amyloidosis-specific treatment prior study inclusion.
Patients participating in other clinical trails for treatment of Amyloidosis.
Pregnancy
Contraindiactions for MRI (eGFR<30ml/min/1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI).
Trial design
Treatments tested in this trial
- Not listed
Trial groups
25 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov